Literature DB >> 26182170

Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.

Stephanie K Fabbro1, Sabrina M Smith1, Jason A Dubovsky2, Alejandro A Gru3, Jeffrey A Jones2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26182170     DOI： 10.1001/jamaoncol.2015.0457

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  10 in total

Review 1.  Covalent Inhibition in Drug Discovery.

Authors:  Avick Kumar Ghosh; Indranil Samanta; Anushree Mondal; Wenshe Ray Liu
Journal:  ChemMedChem       Date:  2019-03-26       Impact factor: 3.466

2.  Campylobacter infection in 4 patients treated with ibrutinib.

Authors:  Boris Sorin; Julien Vigneron; Jehane Fadlallah; Johanna Mondesir; Claire Fieschi; Eric Oksenhendler; Lionel Galicier; Marion Malphettes
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-03-18       Impact factor: 3.267

Review 3.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

4.  Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.

Authors:  Prithviraj Bose; Varsha V Gandhi; Michael J Keating
Journal:  Expert Opin Drug Metab Toxicol       Date:  2016-10-11       Impact factor: 4.481

Review 5.  Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.

Authors:  Jingjing Wu; Mingzhi Zhang; Delong Liu
Journal:  Oncotarget       Date:  2017-01-24

Review 6.  Second-generation inhibitors of Bruton tyrosine kinase.

Authors:  Jingjing Wu; Christina Liu; Stella T Tsui; Delong Liu
Journal:  J Hematol Oncol       Date:  2016-09-02       Impact factor: 17.388

7.  Lower extremity ecchymotic nodules in a patient being treated with ibrutinib for chronic lymphocytic leukemia.

Authors:  Josh A Hammel; Gretchen M Roth; Nkanyezi Ferguson; Janet A Fairley
Journal:  JAAD Case Rep       Date:  2017-04-14

8.  Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

Authors:  Rick A Vreman; Joost W Geenen; Anke M Hövels; Wim G Goettsch; Hubert G M Leufkens; Maiwenn J Al
Journal:  Appl Health Econ Health Policy       Date:  2019-12       Impact factor: 2.561

Review 9.  Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.

Authors:  Anton M Kolomeyer; Christopher K Hwang; Benjamin J Kim
Journal:  J Med Case Rep       Date:  2018-11-16

10.  Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab.

Authors:  Jeffrey Chi; Jennifer Park; Muhammad Wasif Saif
Journal:  Case Rep Oncol Med       Date:  2020-02-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.